Jimin Min
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jimin Min has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Alan J. Simmons
Epithelial Biology Center, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA
1 shared publication- Amy Christine Engevik
Medical University of South Carolina
1 shared publication - Eunyoung Choi
Department of Surgery and Epithelial Biology Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA
1 shared publication James R. Goldenring
Department of Surgery, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA
1 shared publicationJanice A. Williams
Cell Imaging Share Resource, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA
1 shared publicationJoshua W. Betts
Epithelial Biology Center, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA
1 shared publication
Latest Publications
- Open Access
- 5 December 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-16
Heterogeneity and dynamics of active Kras-induced dysplastic lineages from mouse corpus stomach
Dysplasia is considered a key transition state between pre-cancer and cancer in gastric carcinogenesis. However, the cellular or phenotypic heterogeneity and mechanisms of dysplasia progression have not been elucidated. We have established metaplastic and dysplastic organoid lines, derived from Mist1-Kras(G12D) mouse stomach corpus and studied distinct cellular behaviors and characteristics of metaplastic and dysplastic organoids. We also examined functional roles for Kras activation in dysplasia progression using Selumetinib, a MEK inhibitor, which is a downstream mediator of Kras signaling. Here, we report that dysplastic organoids die or show altered cellular behaviors and diminished aggressive behavior in response to MEK inhibition. However, the organoids surviving after MEK inhibition maintain cellular heterogeneity. Two dysplastic stem cell (DSC) populations are also identified in dysplastic cells, which exhibited different clonogenic potentials. Therefore, Kras activation controls cellular dynamics and progression to dysplasia, and DSCs might contribute to cellular heterogeneity in dysplastic cell lineages.
- 5 December 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-16
Open AccessHeterogeneity and dynamics of active Kras-induced dysplastic lineages from mouse corpus stomach
Dysplasia is considered a key transition state between pre-cancer and cancer in gastric carcinogenesis. However, the cellular or phenotypic heterogeneity and mechanisms of dysplasia progression have not been elucidated. We have established metaplastic and dysplastic organoid lines, derived from Mist1-Kras(G12D) mouse stomach corpus and studied distinct cellular behaviors and characteristics of metaplastic and dysplastic organoids. We also examined functional roles for Kras activation in dysplasia progression using Selumetinib, a MEK inhibitor, which is a downstream mediator of Kras signaling. Here, we report that dysplastic organoids die or show altered cellular behaviors and diminished aggressive behavior in response to MEK inhibition. However, the organoids surviving after MEK inhibition maintain cellular heterogeneity. Two dysplastic stem cell (DSC) populations are also identified in dysplastic cells, which exhibited different clonogenic potentials. Therefore, Kras activation controls cellular dynamics and progression to dysplasia, and DSCs might contribute to cellular heterogeneity in dysplastic cell lineages.